Liquid Biopsy for Cancer Diagnostics Pipeline Expected to Advance, Estimates DelveInsight

Key Highlights of Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipelinereport Key Highlights ofLiquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipelinereport Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Insights Cancer is among the leading causes of death worldwide. According to theNational Cancer Institute, the number of new cases per year is expected to rise to23.6 million by 2030. With this growing prevalence of...

Key Highlights of Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipelinereport

Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Insights

Cancer is among the leading causes of death worldwide. According to the National Cancer Institute, the number of new cases per year is expected to rise to 23.6 million by 2030. With this growing prevalence of cancer, there is a need to control it through proper diagnoses and testing. Liquid Biopsy helps utilize circulating biomarkers in the body fluids of cancer patients to provide information regarding the genetic landscape of cancer. It is emerging as a new tool to help in the early detection of cancer.

Various pharmaceutical companies are developing assays, which are marketed such as Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, among others and some of which are in the pipeline such as  CancerIntercept Detect, Exact Science's DNA methylation-based liquid biopsy test, Parsortix, Grail's liquid biopsy cancer test are expected to enter the market by 2026 as effective therapies.

Looking forward to other developments that have taken place in the liquid biopsy diagnostics, three technologies which are being developed comprise of Liquid biopsy next-generation sequencing panel (NuProbe), Liquid Biopsy Test for Prostate Cancer (OncoCell MDx Inc.) and Liquid biopsy RAS biomarker test (Merck/AmoyDx).

The market for Liquid Biopsy for Cancer Diagnostics devices is driven by the increasing prevalence of cancer, increasing preference for non-invasive procedures, availability of funding for liquid biopsy R&D and better turnaround time. Along with this, technological advancements elevating the liquid biopsy market are factors responsible for the growth of the Liquid Biopsy market size at a high CAGR during the forecast period.

Key Competitors in Liquid Biopsy for Cancer Diagnostics Pipeline and Market

Know more about the key companies involved @ Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Insights Key Companies

Table of Content

Visit to know more about the report offerings @ Liquid Biopsy for Cancer Diagnostics Market

The report provides comprehensive insight for clients venturing into the Liquid Biopsy for Cancer Diagnostics devices and acts as the source of guidance for taking strategic business decisions in the field of Liquid Biopsy for Cancer Diagnostics by offering a detailed picture of pathophysiology, various diagnostic approaches, and treatment algorithm including detailed chapters for marketed products and upcoming therapies.

The report portrays a detailed review of both the pipeline and marketed products in 7MM and competitive analysis by understanding the trends shaping and driving the global Liquid Biopsy for Cancer Diagnostics.

This report has been prepared by DelveInsight's analysts after a thorough primary and secondary research into the Liquid Biopsy for Cancer Diagnostics market.

Related Reports

Non-Small Cell Lung Cancer  Market

DelveInsight's 'Non-Small Cell Lung Cancer Market' report.

Pancreatic Cancer Market

DelveInsight's 'Pancreatic Cancer-Market Insights, Competitive Landscape and Market Forecast - 2025' report.

Cervical Cancer Market

DelveInsight's 'Cervical Cancer Market Insight, Epidemiology and Market Forecast -2030' report.

Prostate cancer Market

DelveInsight's 'Prostate cancer Market-Market Insight, Epidemiology and Market Forecast -2030' report.

Vagus Nerve Stimulator Market

DelveInsight's 'Vagus Nerve Stimulator (VNS)-Market Insights, Competitive Landscape and Market Forecast-2025' report.

Patent Foramen Ovale Closure Devices Market

DelveInsight's 'Patent Foramen Ovale (PFO) Closure Devices-Market Insights, Competitive Landscape and Market Forecast-2025' report.

Holter Monitor Market

DelveInsight's 'Holter Monitor (HM)-Market Insights, Competitive Landscape and Market Forecast-2025' report.

Defibrillator Market

DelveInsight's 'Defibrillator-Market Insights, Competitive Landscape and Market Forecast-2025' report.

Visit for Healthcare Consulting Services

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News. 

Contact Us

Shruti Thakur 
[email protected]
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg